BillionToOne

BillionToOne (operating at billiontoone.com) is a precision diagnostics company engineered for making molecular diagnostics more accurate, efficient, and accessible. Founded in 2016 by David Tsao, Oguzhan Atay, and Sukrit Silas, and headquartered in Menlo Park, California, BillionToOne bridges the gap between screening and invasive diagnostics. Under the hood, the company leverages the capture of intact circulating fetal cells using its Unity Confirm test. This allows patients to receive non-invasive confirmation for high-risk screening results. Backed by over $350 million in total venture capital from institutional investors including Adams Street Partners and Hummingbird.